Search Result

Isoforms Recommended:	ATM

Results for "

ATM

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ATM/ATR (38) Ack1 (1) Amyloid-β (1) Apoptosis (8) Autophagy (1) Bacterial (2) Biochemical Assay Reagents (1) Checkpoint Kinase (Chk) (1) CMV (2) DNA-PK (1) DNA/RNA Synthesis (2) FLAP (1) Histone Methyltransferase (1) HSV (2) MDM-2/p53 (1) MicroRNA (1) mTOR (5) Myosin (2) Nucleoside Antimetabolite/Analog (2) PDGFR (1) Phosphatase (1) PI3K (3) PROTACs (2) Reactive Oxygen Species (1) Small Interfering RNA (siRNA) (3) VEGFR (1)
By Research Areas:	Cancer (48) Infection (4) Inflammation/Immunology (2) Neurological Disease (3)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Antibodies

Oligonucleotides

Targets Recommended: ATM/ATR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150617

Lartesertib M4076; ATM Inhibitor-5	ATM/ATR	Cancer
Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase *ATM* (extracted from patent WO2022058351A1) .

HY-100948

ATM-3507	Myosin	Cancer
ATM-3507 is a potent tropomyosin inhibitor with IC₅₀s from 3.83-6.84 μM in human melanoma cell lines.

HY-153787

ATM Inhibitor-6	ATM/ATR	Cancer
ATM inhibitor-6 (A-193) is a selective *ATM* kinase inhibitor. ATM inhibitor-6 can be used in cancer research .

HY-155090

ATM Inhibitor-8	ATM/ATR	Cancer
ATM Inhibitor-8 (Compound 10r) is a highly potent, selective and orally active *ATM* inhibitor,with an IC₅₀ of 1.15 nM. ATM Inhibitor-8 exhibits anti-tumor activity .

HY-142931

ATM-IN-1	ATM/ATR	Neurological Disease Cancer
ATM-IN-1 is a potent inhibitor of *ATM. ATM* is located mainly in the nucleus and microsomes and is involved in cell cycle progression and in the cell cycle checkpoint response to DNA damage. ATM-IN-1 has the potential for the research of cancer and neurology diseases (extracted from patent WO2021139814A1, compound 3) .

HY-155091

ATM Inhibitor-9	ATM/ATR	Cancer
ATM Inhibitor-9 (Compd 7a) is a potent *ATM* inhibitor with IC₅₀5 nM for ATM kinase, useful in cancer research .

HY-144687

ATM Inhibitor-4	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-4 (compound 39) is a potent and selective *ATM* inhibitor, with an IC₅₀ of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability .

HY-144686

ATM Inhibitor-3	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-3 (compound 34) is a potent and selective *ATM* inhibitor, with an IC₅₀ of 0.71 nM. ATM Inhibitor-3 shows inhibition of PI3K kinases family. ATM Inhibitor-3 exhibits favorable metabolic stability .

HY-169310

ATM Inhibitor-11	ATM/ATR	Cancer
ATM Inhibitor-11 (Compound 1) is an inhibitor for *ATM* with an IC₅₀ of 0.32 nM. ATM Inhibitor-11 inhibits the KAP1 phosphorylation with an IC₅₀ of 0.97 nM. ATM Inhibitor-11 exhibits high exposure in the brain, heart and plasma of ICR mouse. ATM Inhibitor-11 exhibits anti-tumor efficacy in NCI-H441 xenograft mouse model .

HY-100948B

ATM-3507 trihydrochloride	Myosin	Cancer
ATM-3507 trihydrochloride is a potent tropomyosin inhibitor with IC₅₀s from 3.83-6.84 μM in human melanoma cell lines.

HY-144685

ATM Inhibitor-2	ATM/ATR	Cancer
ATM Inhibitor-2 (compound 7) is a potent and selective *ATM* inhibitor, with an IC₅₀ of <1 nM .

HY-118911

ATM Inhibitor-10	ATM/ATR	Cancer
ATM Inhibitor-10 (compound 74), a 3-quinoline carboxamide, is a highly selective and orally active *ATM* inhibitor (IC₅₀: 0.6 nM). ATM Inhibitor-10 has anti-tumor activity in SW620 xenograft models. ATM Inhibitor-10 is synergistic with Top I inhibitors .

HY-149291

ATM Inhibitor-7	ATM/ATR Apoptosis	Cancer
ATM Inhibitor-7 is a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor with an IC₅₀ value of 1.0 nM. ATM Inhibitor-7 induces Apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11 (HY-16562). ATM Inhibitor-7 combines with CPT-11 shows antitumor activity .

HY-112614

ATM Inhibitor-1	ATM/ATR	Cancer
ATM Inhibitor-1 is a highly potent, selective and orally active *ATM* inhibitor, with an IC₅₀ of 0.7 nM, shows weak activity against mTOR (IC₅₀, 21 μM), DNAPK (IC₅₀, 2.8 μM), PI3Kα (IC₅₀, 3.8 μM), PI3Kβ (IC₅₀, 10.3 μM), PI3Kγ (IC₅₀, 3 μM) and PI3Kδ (IC₅₀, 0.73 μM). ATM Inhibitor-1 exhibits anti-tumor activity .

HY-RS01160

ATM Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ATM Human Pre-designed siRNA Set A contains three designed siRNAs for ATM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ATM Human Pre-designed siRNA Set A ATM Human Pre-designed siRNA Set A

HY-RS01161

Atm Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Atm Mouse Pre-designed siRNA Set A contains three designed siRNAs for Atm gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Atm Mouse Pre-designed siRNA Set A Atm Mouse Pre-designed siRNA Set A

HY-RS01162

Atm Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Atm Rat Pre-designed siRNA Set A contains three designed siRNAs for Atm gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Atm Rat Pre-designed siRNA Set A Atm Rat Pre-designed siRNA Set A

HY-150617A

(Rac)-Lartesertib (Rac)-M4076; (Rac)-ATM Inhibitor-5	ATM/ATR	Cancer
(Rac)-Lartesertib ((Rac)-M4076; (Rac)-ATM Inhibitor-5) is an isoform of Lartesertib (HY-150617), which is a potent inhibitor of serine/threonine protein kinase *ATM* (extracted from patent WO2022058351A1) .

HY-162002

WSD0628	ATM/ATR	Cancer
WSD0628 is a brain penetrant and potent *ATM* inhibitor with profound radiosensitizing effect .

HY-157941

ART0380	ATM/ATR	Cancer
ART0380 is a potent and selective ATR kinase inhibitor. ART0380 has selective antitumor activity that can be used for the research of Ataxia-Telangiectasia Mutated (ATM) aberrant cancers .

HY-158345

PROTAC VHL-type degrader-1	PROTACs	Cancer
PROTAC VHL-type degrader-1 (compound 9b) is a VHL-type PROTAC degrader. PROTAC VHL-type degrader-1 induces ATM degradation synergistically enhancing the efficacy of ATR inhibitor AZD6738 .

HY-112477

Chk2-IN-1	Checkpoint Kinase (Chk)	Cancer
Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC₅₀s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect .

HY-19959

(Z)-Mirin 5 Publications Verification	ATM/ATR Apoptosis	Cancer
(Z)-Mirin is an MRN (Mre11-Rad50-Nbs1) inhibitor. (Z)-Mirin prevents MRN-dependent activation of ATM without affecting ATM protein kinase activity. (Z)-Mirin inhibits Mre11-associated exonuclease activity. (Z)-Mirin increases apoptosis, triggers a G2/M checkpoint and strongly inhibits homology-directed repair (HDR) .

HY-160096

M3541	ATM/ATR	Cancer
M3541 is a potent, ATP-competitive and selective *ATM* inhibitor with an IC₅₀ of 0.25 nM. M3541 shows remarkable selectivity against other protein kinases. M3541 suppresses double-strand breaks (DSB) repair and has antitumor activities .

HY-112305

AZ32	ATM/ATR	Cancer
AZ32 is an orally bioavailable and blood-brain barrier-penetrating *ATM* inhibitor with an IC₅₀ of <6.2 nM for ATM enzyme, and an IC₅₀ of 0.31 μM for ATM in cell.

HY-16705

BRD4770 3 Publications Verification	Histone Methyltransferase	Cancer
BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of lysine 9 on histone H3 (H3K9) with an EC₅₀ of 5 μM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .

HY-18650

KU 59403	ATM/ATR	Cancer
KU 59403 is a potent *ATM* inhibitor, with IC₅₀ values of 3 nM, 9.1 μM and 10 μM for ATM, DNA-PK and PI3K, respectively .

HY-112198

AZ31	ATM/ATR	Cancer
AZ31 is a a potent, highly selective, and orally active *ATM* inhibitor with an IC₅₀ of <1.2 nM for ATM enzyme, and an IC₅₀ of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .

HY-141478

Antitumor agent-28	ATM/ATR	Cancer
Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity .

HY-103241

Ro 90-7501 2 Publications Verification	Amyloid-β ATM/ATR Phosphatase Apoptosis	Neurological Disease Cancer
Ro 90-7501 is an amyloid β₄₂ (Aβ₄₂) fibril assembly inhibitor that reduces Aβ₄₂-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits *ATM* phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .

HY-100016

AZD0156 5+ Cited Publications	ATM/ATR Apoptosis	Cancer
AZD0156 is a potent, selective and orally active *ATM* inhibitor with an IC₅₀ of 0.58 nM. AZD0156 inhibits the *ATM*-mediated signaling, prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis .

HY-15520

CGK733 5 Publications Verification	ATM/ATR	Cancer
CGK733 is a potent *ATM/ATR* inhibitor, used for the research of cancer.

HY-123834

FEN1-IN-1 5 Publications Verification	FLAP ATM/ATR	Cancer
FEN1-IN-1 (compound 1) is a small molecule flap endonuclease 1 (FEN1) inhibitor with antitumor activity. FEN1-IN-1 binds to the active site of FEN1 and partly achieves inhibition by the co-ordination of Mg ²⁺ ions. FEN1-IN-1 initiaties a DNA damage response and activates the ATM checkpoint signalling pathway, the phosphorylation of histone H2AX and the ubiquitination of FANCD2 in mammalian cells. FEN1-IN-1 is promising for research of cancers .

HY-12016

KU-55933 Maximum Cited Publications 39 Publications Verification	ATM/ATR Autophagy	Cancer
KU-55933 is a potent *ATM* inhibitor with an IC₅₀ and K_i of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

HY-12061

KU-60019 15+ Cited Publications	ATM/ATR	Cancer
KU-60019 is an improved *ATM* kinase-specific inhibitor with IC₅₀ of 6.3 nM.

HY-13902

Berzosertib 10+ Cited Publications VE-822; VX-970; M6620	ATM/ATR	Cancer
Berzosertib (VE-822) is an ATR inhibitor with a K_i value of less than 0.2 nM. It also inhibits *ATM* with a K_i of 34 nM.

HY-117693

Mirin 2 Publications Verification	ATM/ATR	Cancer
Mirin is a potent Mre11-Rad50-Nbs1 (MRN) complex inhibitor. Mirin prevents MRN-dependent activation of ATM (IC₅₀=12 μM) without affecting ATM protein kinase activity, and it inhibits Mre11-associated exonuclease activity. Mirin abolishes the G2/M checkpoint and homology-dependent repair in mammalian cells. Mirin prevents ATM activation in response to DNA double-strand breaks (DSBs) and blocks homology-directed repair (HDR) in mammalian cells .

HY-109566

AZD1390 5+ Cited Publications	ATM/ATR	Inflammation/Immunology Cancer
AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant *ATM* inhibitor with an IC₅₀ of 0.78 nM in cell .

HY-151915

ATR-IN-20	ATM/ATR mTOR	Cancer
ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC₅₀ of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC₅₀ of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .

HY-136835

GJ071 oxalate	ATM/ATR	Neurological Disease
GJ071 oxalate induces ATM kinase activity in ataxia telangiectasia (A-T) cells carrying homozygous TGA or TAG stop codons .

HY-126210

GJ072	Biochemical Assay Reagents	Others
GJ072 is a read-through compound (RTCs). GJ072 can induce “readthrough” .

HY-157767

Abd110	PROTACs ATM/ATR	Cancer
Abd110 (compound 42i) is a Lenalidomide-based PROTAC ATR kinase degrader. Abd110 selectively decreases ATR and phospho-ATR without affecting related kinases ATM and DNA-PKcs .

HY-144217

SKLB-197	ATM/ATR	Cancer
SKLB-197 showed an IC₅₀ value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.

HY-P2096

Hexapeptide-11	Reactive Oxygen Species ATM/ATR MDM-2/p53	Infection
Hexapeptide-11 is a bioactive peptide with anti-aging effect. Hexapeptide-11 protects fibroblasts against oxidative stress-mediated premature cellular senescence by mediating a downregulation of cellular proteins, such as ataxia telangiectasia mutated (ATM) and p53 .

HY-11002

CP-466722 5 Publications Verification	ATM/ATR	Cancer
CP-466722 is a rapidly reversible inhibitor of *ATM, with an IC₅₀* of 0.41 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members.

HY-123359

RTC14	Others	Others
RTC14 is a read-through compound (RTC) that can induce ribosomes to bypass nonsense mutations in mRNA and allow the production of full-length functional proteins. RTC14 has the potential to be used in the research of various genetic disorders, such as nonsense mutations in the ataxia-telangiectasia mutated (ATM) gene and the dystrophin gene .

HY-118921

Ovatodiolide	Apoptosis	Infection Inflammation/Immunology Cancer
Ovatodiolide is a compound that can be isolated from Anisomeles indica. Ovatodiolide has anti-bacterial and anti-inflammatory properties. Ovatodiolide also has anti-cancer activity that induces cell cycle G2/M arrest and apoptosis via a ROS-dependent ATM/ATR signaling pathways .

HY-162472

XRD-0394	ATM/ATR DNA-PK	Cancer
XRD-0394 is a potent and specific dual inhibitor of *ATM* and DNA-PKcs with oral activity. XRD-0394 significantly enhances tumor cell killing in vitro and in vivo under therapeutic ionizing radiation conditions. In addition, XRD-0394 can potentiate the effects of PARP and topoisomerase I inhibitors in vitro .

HY-169121

DA-143	mTOR PI3K	Cancer
DA-143 is a selective DNA-PKcs inhibitor (IC₅₀: 2.5 nM), and the IC₅₀s for mTOR, PI3KΔ, and ATM are 280 nM, 106 nM and 6,594 nM respectively. DA-143 blocks phosphorylation of DNA-PKcs substrates. DA-143 sensitizes cancer cells to Doxorubicin (HY-15142) .

HY-15290

AIM-100 3 Publications Verification	Ack1	Cancer
AIM-100 is a potent and selective Ack1 inhibitor with an IC₅₀ of 21.58 nM. AIM-100 also inhibits Tyr ²⁶⁷ phosphorylation. AIM-100 does not inhibits other kinases including PI3-kinase and AKT subfamily members. AIM-100 has an anticancer effect .

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library

2,144 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,144 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

HY-L004

Cell Cycle/DNA Damage Compound Library

2,377 compounds

DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.

MCE owns a unique collection of 2,377 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Cat. No.	Product Name	Target	Research Area

HY-P2096

Hexapeptide-11	Reactive Oxygen Species ATM/ATR MDM-2/p53	Infection
Hexapeptide-11 is a bioactive peptide with anti-aging effect. Hexapeptide-11 protects fibroblasts against oxidative stress-mediated premature cellular senescence by mediating a downregulation of cellular proteins, such as ataxia telangiectasia mutated (ATM) and p53 .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80023

	ATM Antibody	WB, ICC/IF, IHC-P	Human
	ATM Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 351 kDa, targeting to ATM. It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human.

HY-P80453

	*Phospho-ATM* (S1981) Antibody**	WB, ICC/IF, IHC-P, IP	Human
	Phospho-ATM (S1981) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 351 kDa, targeting to Phospho-ATM (S1981). It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human.

HY-P83436

	*Phospho-ATM* (Ser1981) Antibody (YA3181)** ATM; Serine-protein kinase ATM; Ataxia telangiectasia mutated; A-T mutated	WB, IHC-P, ICC/IF, IP	Human
	Phospho-ATM (Ser1981) Antibody (YA3181) is a biotin-conjugated non-conjugated IgG antibody, targeting Phospho-ATM (Ser1981), with a predicted molecular weight of 351 kDa. Phospho-ATM (Ser1981) Antibody (YA3181) can be used for WB, IHC-P, ICC/IF, IP experiment in human background.

HY-P82549

	BRAT1 Antibody (YA2294) BRCA1-associated ATM activator 1; BRCA1-associated protein required for ATM activation protein 1	WB, ICC/IF, IP	Human
	BRAT1 Antibody (YA2294) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2294), targeting BRAT1, with a predicted molecular weight of 88 kDa (observed band size: 88 kDa). BRAT1 Antibody (YA2294) can be used for WB, ICC/IF, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks